Antibody conjugates against variant NFKBIB and uses thereof
AssigneeViventia Bio Inc.
InventorsFrancina C. Chahal, Jeannick Cizeau
Life of this patent
Estimating the term…
Abstract
The present application provides the amino acid and nucleic acid sequences of heavy and light chain complementarity determining regions of a cancer specific antibody directed to an epitope of variant Nuclear Factor Kappa-B inhibitor beta (NFKBIB). In addition, the application provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or a label, and methods of uses thereof. The application also relates to diagnostic methods and kits using the cancer specific antibodies herein. Further, the application provides novel cancer-associated epitopes and antigens of variant NFKBIB, and uses thereof.
Claims29
A recombinant antibody comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:
- 4 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
- 2.
A recombinant antibody comprising:
- light chain complementarity determining regions comprising the amino acid sequences defined by SEQ ID NOS:
- 8, 9 and 10 and
- heavy chain complementarity determining regions comprising the amino acid sequences defined by SEQ ID NOS:
- 5, 6 and 7.
An immunoconjugate comprising an antibody attached to a cancer therapeutic, wherein the antibody comprises light chain complementarity determining regions having the amino acid sequences defined by SEQ ID NOS:
- 8, 9 and 10, and heavy chain complementarity determining regions having the amino acid sequences defined by SEQ ID NOS:
- 5, 6 and 7.
A immunoconjugate comprising an antibody attached to a cancer therapeutic, wherein the antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:
- 4, and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
- 2.
Dependencies are inferred from the claim text.